There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the ...
Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...
Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...
Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in ...
Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...
In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback